The door has finally opened on screening newborn babies for pyridoxine-dependent epilepsy (PDE), a severe inherited metabolic disorder. This screening promises to enable better and earlier treatment of the disease. To identify new biomarkers that can be used in the newborn screening protocol, also known as the neonatal heel prick, researchers at the Radboud University Medical Center joined forces with scientists at the Radboud University’s HFML-FELIX laboratory. They published their findings in The Journal of Clinical Investigation.
The discovery and identification of the new biomarkers could lead to an important addition to worldwide newborn screening protocols. Currently, there are over a thousand known inborn metabolic diseases (IMD), but only 2% of them can be detected through the neonatal heel prick. While these are relatively rare as individual disorders, in the Netherlands, every other day a child is born with an IMD. These disorders have severe health consequences for patients and are currently one of the leading causes of early death among children in the Netherlands.
“Using new techniques in our clinical laboratory where we study the products of chemical processes (metabolomics), we were able to detect the presence of compounds in body fluids of patients that are not present in persons unaffected by PDE – that was a great first step. However, we could only identify the exact structure of these compounds, the new PDE biomarkers, using the infrared laser at FELIX”, says Karlien Coene, laboratory specialist and researcher at the Translational Metabolic Laboratory of the Radboud University Medical Center. This is the first time that an infrared free electron laser – of which are only a hand full in the world – is combined with these clinical experiments.
Pyridoxine-dependent epilepsy (PDE) is an inherited metabolic disorder that is primarily characterized by intractable seizures that do not respond to conventional antiepileptic medications. Seizures are often controlled by daily high doses of vitamin B6, however 80% of affected children nevertheless suffer developmental delay and intellectual disability.
Early screening for metabolic diseases is critical for optimal treatment. That is why researchers are constantly looking for new ways to detect more metabolic diseases earlier in life via the heel prick. These diseases can be identified by looking for the presence of small molecules in the blood that are unique to the disease, also called “biomarkers”.
Biomarker discovery and identification is a well-known bottleneck in research of metabolic diseases. “To overcome this hurdle, we decided to combine the advanced analytical instrumentation with the infrared laser of the FELIX laboratory’, says Jonathan Martens, researcher at Radboud University’s FELIX Laboratory. “The measurements obtained using the unique FELIX laser gives us information about the bonds between the atoms and leads us to the precise molecular structure. With this information, we ultimately managed to synthesize the molecules and this allowed us to further investigate their role in the disease.”
In addition to new possibilities in newborn screening, this finding has also revealed fundamental insights about the disease, which could ultimately lead to optimized treatment and better chances to prevent cognitive disability.
Martens: “Now that we have demonstrated that this new combination of techniques really works, we are actively applying our method in research on a range of other (metabolic) diseases for which biomarkers are currently lacking.”
Related news items
Dutch-Nordic Alliance for Precision Cancer Medicine launched26 November 2021
The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.read more
Last chance - Call for nominations Supervisor of the Year & Image award25 November 2021
The RIMLS PhD Council has extended the deadline to 1 December to nominate supervisors and images for the supervisor of the year and image awards. Send in your nominations while you still can!read more
The effects of dopamine levels on reward responsivity25 November 2021
To adapt to the ever-changing context in which we live, we are constantly deciding how much effort to put into performing our behavior, or how fast to perform our actions. How do people decide how fast to act and how does the brain compute this? Our researchers set out to investigate this.read more
RIMLS PhD retreat - review organized during New Frontiers 202123 November 2021
This year's RIMLS PhD retreat 2021 was an online event, combined with the New Frontiers symposium. Organized by and for RIMLS PhD candidates, the retreat was again received with great enthusiasm of the attendees.read more